Bandingkan kaedah

	Formulasi Dispersi Pepejal	Ujian Kebolehtelapan Sel Caco-2	Faktor Keserupaan f1/f2 Pembubaran
Bidang	Farmakologi	Farmakologi	Farmakologi
Keluarga	Process / pipeline	Process / pipeline	Process / pipeline
Tahun asal	1971	1989	1996
Pengasas	William Chiou and Solomon Riegelman	Ingrid Hidalgo	James Moore and Hector Flanner
Jenis	solubility enhancement	absorption screening	similarity testing
Sumber perintis	Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302.	Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749.	Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74.
Alias	solid solution, amorphous dispersion, polymer-based formulation	Caco-2 assay, intestinal permeability, ADME screening	f1, f2, similarity factor
Berkaitan	3	3	3
Ringkasan	Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption.	The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport.	The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release.